RFK Jr. peptide policy could boost Hims & Hers as its GLP-1 business changes

Key Points:

• Hims & Hers Health shares surged after the FDA announced plans to review peptides for inclusion on the 503A bulk list, potentially allowing individualized compounding rather than mass production.
• Expanding peptide compounding could create new revenue streams for Hims as it shifts focus from branded GLP-1 drugs to compounded peptide therapies.
• Peptides, short amino acid chains with various health uses, remain controversial due to limited scientific evidence and unregulated production, but Hims acquired a peptide facility in 2025 to build its peptide business.
• FDA’s review, supported by HHS Secretary Robert F. Kennedy Jr., aims to regulate peptide therapies more formally, moving them from the "gray market" into physician-led care, though clinical validation is still limited.
• Analysts view the FDA’s peptide review as a positive long-term growth opportunity for Hims, but caution that revenue impact will take time, with regulatory changes expected to be gradual following an advisory meeting in July.